Indication assessment · Cardiovascular
Atherogenic dyslipidaemia — indication assessment
An adverse lipoprotein profile, typically raised triglycerides with reduced HDL cholesterol and a raised apolipoprotein B to apolipoprotein A1 ratio.
§1Assessment
§1.1Definition
An adverse lipoprotein profile, typically raised triglycerides with reduced HDL cholesterol and a raised apolipoprotein B to apolipoprotein A1 ratio.
§1.2Anchor and additional outcomes
The Institute designates one anchor outcome per indication so that estimates for different compounds are reported on a common measure. The anchor for this indication is the first outcome below.
- Change in triglycerides
- Change in LDL and non-HDL cholesterol
- Change in apolipoprotein B
- Change in lipoprotein(a)
§1.3State of the evidence
HighModerateLowVery low
No compound in the Institute's set has an assessed outcome in this indication. No compound is graded above low certainty in this indication, which the Institute records as the principal finding for it.
Compound Evidence Institute · CEI-IN-18 · https://compoundevidence.com/indications/dyslipidaemia/ · retrieved 30 July 2026